Minerva Neurosciences | NERV - Créanciers Commerciaux





Créanciers Commerciaux Changement Date
Acadia Pharmaceuticals USD 12.25M 1.34M 2026-03
Adma Biologics USD 20.52M 2M 2026-03
ALKERMES USD 102.36M 5.59M 2026-03
Alterity Therapeutics Limited AUD 1.07M 203.72K 2025-12
AstraZeneca USD 22.51B 2.78B 2026-03
BioCryst Pharmaceuticals USD 10.96M 4.87M 2026-03
Bristol-Myers Squibb USD 4.23B 659M 2026-03
Cipla INR 32.3B 1.95B 2026-03
Clal Biotechnology ILS 21.05M 1.62M 2021-12
Compugen USD 2.35M 6.77M 2025-12
CSL USD 3.17B 290M 2025-12
Eli Lilly USD 5.03B 350M 2026-03
Esperion Therapeutics USD 68.41M 3.34M 2026-03
GlaxoSmithKline GBP 14.34B 1.05B 2026-03
Grifols EUR 987.75M 47.87M 2025-12
Halozyme Therapeutics USD 14.1M 6.8M 2026-03
Ionis Pharmaceuticals USD 26.03M 2.05M 2026-03
J&J USD 10.46B 1.53B 2026-03
Merck USD 3.86B 541M 2026-03
Minerva Neurosciences USD 640K 305K 2025-12
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Novartis USD 4.32B 134M 2026-03
Novavax USD 16.1M 8.48M 2026-03
Pfizer USD 4.51B 734M 2026-03
Roche Holding CHF 5.78B 1.27B 2025-12
Sanofi EUR 22.71B 219M 2026-03
Takeda JPY 491.34B 23.75B 2026-03
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12